Sandbox Reserved 1237
From Proteopedia
Line 31: | Line 31: | ||
== Structural highlights == | == Structural highlights == | ||
- | Verotoxin-1 exists as hetero-hexamer (~74300 Da), made up of an A and B subunit. The A-subunit, a monomer, is ~32000 Da, while each of the five chains of the B-subunit pentamer is ~8000-8500 Da. Thus, the protein stoichiometry is A5B. The A By itself, the B subunit has cyclic C5 symmetry. It is the A subunit that causes disease via catalytically inactivating 60S ribosomal subunit by cleaving into subunits A1 and A2 via furin, A1 being the catalytic unit and A2 being the unit binding A1 to the β pentamer. The role of the B subunit is to bind to receptors on target cells, most notably globotriaosylceramide (Gb3) in humans. There are three Gb3 binding sites within the B subunit, sites 1 and 2 having a higher affinity than site 3. Thus, the A subunit is the disease-causing subunit. The A1 subunit contains ten alpha-helices and thirteen beta-strands while the A2 subunit contain two alpha-helices and two beta-strands. The A2 subunit is also entirely hydrophilic while the A1 subunit has regions of hydrophobicity, likely due to its function as a catalytic inhibitor of the 60S subunit. The B subunit is largely hydrophilic with one region of hydrophobicity, which are alpha-to-beta transitions on the outer side of the pentamer. [1][2] | + | Verotoxin-1 exists as hetero-hexamer (~74300 Da), made up of an A and B subunit. The A-subunit, a monomer, is ~32000 Da, while each of the five chains of the B-subunit pentamer is ~8000-8500 Da. Thus, the protein stoichiometry is A5B. The A By itself, the B subunit has cyclic C5 symmetry. It is the A subunit that causes disease via catalytically inactivating 60S ribosomal subunit by cleaving into subunits A1 and A2 via furin, A1 being the catalytic unit and A2 being the unit binding A1 to the β pentamer. The role of the B subunit is to bind to receptors on target cells, most notably globotriaosylceramide (Gb3) in humans. There are three Gb3 binding sites within the B subunit, sites 1 and 2 having a higher affinity than site 3. Thus, the A subunit is the disease-causing subunit. The A1 subunit contains ten alpha-helices and thirteen beta-strands while the A2 subunit contain two alpha-helices and two beta-strands. The A2 subunit is also entirely hydrophilic while the A1 subunit has regions of hydrophobicity, likely due to its function as a catalytic inhibitor of the 60S subunit. The B subunit is largely hydrophilic with one region of hydrophobicity, which are alpha-to-beta transitions on the outer side of the pentamer. <sup>[1][2]</sup> |
== Evolution == | == Evolution == |
Current revision
This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
Verotoxin-2
|
References
1. Fraser ME, et al. "Structure of Shiga Toxin Type 2 (Stx2) from Escherichia Coli O157:H7." J.Biol.Chem. 279(26). (2004). 27511-7
2. http://www.rcsb.org/pdb/explore/explore.do?structureId=1R4P
3. Römer W, et al. "Shiga toxin induces tubular membrane invaginations for its uptake into cells." Nature. (2007). 450(7170):670-675
4. Ray PE, Lui XH. "Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome." Pediatr Nephrol. 2001. 16(10):823-39
5. O'Loughlin EV, Robins-Brown RM. "Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells." Microbes Infect. (2001). 3(6):492-507
6. Melton-Celsa AR. “Shiga Toxin (Stx) Classification, Structure, and Function.” Microbiology spectrum. (2014). 2(2):PMC
7. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. "Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals." Toxins. (2012). 4(11):1261-1287
8. McGannon1 CM, Fuller CA, Weiss AA. "Different Classes of Antibiotics Differentially Influence Shiga Toxin Production." Antimicrob. Agents Chemother. (2010). 54(9):3790-3798
9. Bielaszewska M, et al. "Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain" Antimicrob. Agents Chemother. (2012). 56(6):3277-3282
10. Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. "Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype." Frontiers in Cellular and Infection Microbiology. (2015). 5(24):PMC
11. Law, D. "The history and evolution of Escherichia coli O157 and other Shiga toxin-producing E. coli". World Journal of Microbiology and Biotechnology. (2000). 16(8):701-709.
12. Martínez-Castillo A, Muniesa M. "Implications of free Shiga toxin-converting bacteriophages occurring outside bacteria for the evolution and the detection of Shiga toxin-producing Escherichia coli." Frontiers in Cellular and Infection Microbiology. (2014). 4(46):PMC
13. O'Brien AD, Holmes RK. "Shiga and Shiga-like toxins." Microbiological Reviews. (1987). 51(2):206-220